联合用药治疗肝纤维化的研究概况与展望

doi:10.19803/j.1672-8629.20240273

摘要/Abstract

摘要： 目的探讨联合用药在肝纤维化（HF）治疗领域的研究现状以及未来展望。方法回顾国内外相关文献,总结该领域的研究成果,讨论HF治疗的关键问题,包括发病机制、现有药物治疗方法及联合用药治疗的主要进展。结果 HF的发病机制主要涉及肝星状细胞激活、铁死亡、细胞自噬以及细胞传导通路。目前应用的单药治疗虽然在控制病情上取得了一定成效,但治疗效果有限且可能面临药物耐药性等问题。联合用药由于其多靶点、多途径的作用机制,已成为治疗HF的研究热点。国内外研究表明,某些联合用药能够显著抑制病理过程、改善肝功能指标,且在减轻HF、提高预后方面作用突出。结论多药物联合治疗是治疗HF的有效策略之一,尤其在处理复杂病理机制和多因素影响的情况下作用突出。建议未来研究进一步优化联合治疗方案,复方药物开发可能成为新药研究的新趋势。

关键词: 肝纤维化, 肝星状细胞, 细胞外基质, 发病机制, 联合用药, 复方药物

Abstract: Objective To summarize the current research and prospects of drug combinations used in the treatment of hepatic fibrosis(HF). Methods Related literature at home and abroad was reviewed, research findings in this field were summarized, and the key issues facing HF treatment were discussed, including the pathogenesis, medications currently used and the progress in drug combination therapies. Results The pathogenesis of HF involved hepatic stellate cell activation, iron death, autophagy and cell conduction pathway. Despite the benefits of monotherapy in controlling the disease, the therapeutic effect was limited and such problems as drug resistance existed. Because of the multi-target and multi-pathway mechanism of action, drug combinations became a hot spot in the treatment of HF. Studies showed that some drug combinations could significantly inhibit pathological processes, improve liver function indexes, and go a long way towards alleviating HF and improving prognosis. Conclusion Multi-drug combination therapies are one of the effective strategies for HF treatment, especially in case of complex pathological mechanism and multi-factor influence. It is recommended that future studies continue to optimize the combination treatment regimens. The development of compound drugs may become a new trend in new drug research.

Key words: hepatic fibrosis, hepatic stellate cells, extracellular matrix, pathogenesis, combination drugs, compound drugs

中图分类号:

R916
R975

申雪, 江海燕, 范潇予, 李万芳, 包捷, 何博赛, 靳洪涛. 联合用药治疗肝纤维化的研究概况与展望[J]. 中国药物警戒, 2024, 21(9): 985-990.

SHEN Xue, JIANG Haiyan, FAN Xiaoyu, LI Wanfang, BAO Jie, HE Bosai, JIN Hongtao. Developments in research on combination drugs for hepatic fibrosis[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 985-990.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240273

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I9/985

参考文献

[1] LI XM, WANG WB, GUO LN, et al.Improvement effects of chelidonine on CCl₄-induced hepatic fibrosis model rats and its mechanism[J]. China Pharmacy(中国药房), 2021, 32(23): 2868-2874.
[2] LIU JH, LI XY, WANG ML, et al.Advantages and characteristics of traditional Chinese medicine in the treatment of liver fibrosis[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2023, 39(2): 267-272.
[3] PINZANI M, MACIAS-BARRAGAN J.Update on the pathophysiology of liver fibrosis[J]. Expert Review of Gastroenterology & Hepatology, 2014, 4(4): 459-472.
[4] LI K, NING HB, SHANG J.Recent advances in clinical studies on hepatitis B virus infection and liver cancer[J]. Journal of Southwest Medical University(西南医科大学学报), 2021, 44(6): 607-611.
[5] FENG GS.Effect of liver-sparing and spleen-strengthening formula combined with adefovir dipivoxil capsule on liver fibrosis index in HBeAg positive chronic hepatitis B patients[J]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine(实用中西医结合临床), 2021, 21(11): 78-79.
[6] CHEN XX.Long-term efficacy analysis of entecavir and telbivudine in the treatment of patients with chronic hepatitis B with high viral load[J]. Contemporary Medicine(当代医学), 2020, 26(30): 184-186.
[7] JING HP, XIONG SB, PAN WS.Thinking and strategies of developing new compound preparations to overcome adverse drug reactions[J]. Central South Pharmacy(中南药学), 2014, 12(6): 512-517.
[8] MICHALOPOULOS GK, BHUSHAN B.Liver regeneration: biological and pathological mechanisms and implications[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 40-55.
[9] LI QQ, YANG HS, LI JD, et al.Research progress on pathogenesis of liver fibrosis and anti-liver fibrosis of traditional Chinese medicine[J]. Journal of Jianghan University (Natural Science Edition)(江汉大学学报自然科学版), 2023, 51(3): 75-81.
[10] SCHUPPAN D, ASHFAQ-KHAN M, YANG AT, et al.Liver fibrosis: direct antifibrotic agents and targeted therapies[J]. Matrix Biol, 2018(68-69): 435-451.
[11] ALDROVANDI M, CONRAD M.Ferroptosis: the good, the bad and the Ugly[J]. Cell Res, 2020, 30(12): 1061-1062.
[12] LIANG RJ,, LIANG R, LI JM, et al.Autophagy-based pathogenesis of liver fibrosis and potential intervention effect of Zhuanggan Zhuyu ecoction[J]. Guangxi Medical Journal(广西医学), 2021, 43(19): 2355-2358.
[13] ZHOU HX, LU YB.Research progress of traditional Chinese medicine regulating TGF-β1/Smad signaling pathway in the prevention and treatment of hepatic fibrosis[J]. Clinical Journal of Traditional Chinese Medicine(中医药临床杂志), 2024, 36(1): 187-191.
[14] WANG FD, ZHOU J, CHEN EQ.Molecular mechanisms and potential new therapeutic drugs for liver fibrosis[J]. Front Pharmacol, 2022, 13: 787748.
[15] LIU Z, LI C, KANG N, et al.Transforming growth factor β (TGFβ) cross-talk with the unfolded protein response is critical for hepatic stellate cell activation[J]. J Biol Chem, 2019, 294(9): 3137-3151.
[16] WANG QS, SUN Y, LIU TY, et al.Study on the role of ferroptosis in the pathogenesis of liver fibrosis induced by carbon tetrachloride[J]. Modern Preventive Medicine(现代预防医学), 2022, 49(12): 2241-2246.
[17] PAN Q, LUO Y, XIA Q, et al.Ferroptosis and liver fibrosis[J]. Int J Med Sci, 2021, 18(15): 3361-3366.
[18] XU D, CHEN Q, YANG LX, et al.Screening of natural drug components for the treatment of liver fibrosis based on ferroptosis perspective[J]. Pharmacy Today(今日药学), 2024, 34(4): 1-13.
[19] ZHOU X, YU L, ZHOU M, et al.Dihydromyricetin ameliorates liver fibrosis via inhibition of hepatic stellate cells by inducing autophagy and natural killer cell-mediated killing effect[J]. Nutr Metab(Lond), 2021, 18(1): 64.
[20] LI F, QIU Y, XIA F, et al.Dual detoxification and inflammatory regulation by ceria nanozymes for drug-induced liver injury therapy[J]. Nano Today, 2020, 35: 100925.
[21] ZHANG XW, ZHOU JC, PENG D, et al.Disrupting the TRIB3-SQSTM1 interaction reduces liver fibrosis by restoring autophagy and suppressing exosome-mediated HSC activation[J]. Autophagy, 2019, 16(5): 1-14.
[22] CHEN LX.COX-2 inhibits autophagy of HSC-T6 through PI3K/AKT/MTOR signaling pathway[D]. Hengyang: University of South China, 2023.
[23] SONG Y, WEI J, LI R, et al.Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-β/SMAD signaling[J]. Hepatology, 2023, 78(5): 1433-1447.
[24] FABREGAT I, CABALLERO-DÍAZ D. Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis[J]. Front Oncol, 2018, 8: 357.
[25] WU FR, JIANG L, HE XL, et al.Effect of hesperidin on TGF-β1 /Smad signaling pathway in HSC[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2015, 40(13): 2639-2643.
[26] WEI L, CHEN Q, GUO A, et al.Asiatic acid attenuates CCl₄-induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways[J]. International Immunopharmacology, 2018, 60: 1-8.
[27] LUO X, QU Y, CAI XB, et al.Effects of antiviral therapy on the reversal of liver fibrosis[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2022, 38(11): 2596-2598.
[28] GUO M, WANG Z, DAI J, et al.Glycyrrhizic acid alleviates liver fibrosis in vitro and in vivo via activating CUGBP1-mediated IFN-γ/STAT1/Smad7 pathway[J]. Phytomedicine, 2023, 112: 154587.
[29] WANG L, HUANG JB, HUANG YQ, et al.Effects of curcumol on iron death and epithelial-mesenchymal transition inhepatic stellate cells[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2024, 40(4): 539-543.
[30] DAI QL.Clinical observation of Qizhu granules in the treatment of liver fibrosis and its mechanism based on autophagy of hepatic stellate cells[D]. Beijing: China Academy of Chinese Medical Sciences, 2024.
[31] ZHOU LH, CHEN X.Geniposide inhibits hepatic fibrosis and hepatic stellate cell activation through blocking the TGF-β1/smad signaling pathway[J]. Acta Physiologica Sinica(生理学报), 2022, 74(2): 217-224.
[32] CAO JF, SUN Y, DING X, et al.Arbutin ameliorates liver fibrosis in mice by inhibiting macrophage recruitment and regulating the Akt/NF-κB and Smad signaling pathways[J]. Journal of Southern Medical University(南方医科大学学报), 2024, 44(4): 652-659.
[33] YAO HJ, CHEN HX, LI HY.Research progress of compound Biejia Ruangan tablet for prevention and treatment of liver fibrosis[J]. Chinese Medical Journal of Metallurgical Industry(中国冶金工业医学杂志), 2022, 39(3): 261-263.
[34] HUANG X, MENG XJ, WU S.The effect of Fuzheng Huayu capsules(FZHY) on the development of hepatic fibrosis[J]. Chinese Hepatology(肝脏), 2024, 29(4): 429-431, 452.
[35] DOU J.Study on the mechanism of Hexue Rougan decoction anti hepatic fibrosis by inducing ferroptosis of hepatic stellate cells through NOX4/ROS pathway[D]. Urumqi: Xinjiang Medical University, 2023.
[36] NIE M, LU WJ, WANG J.Clinical study on compound Biejia ruangan tablets combined with entecavir for hepatitis B cirrhosis[J]. New Chinese Medicine(新中医), 2021, 53(1): 187-190.
[37] RONG G, CHEN Y, YU Z, et al.Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: a multicenter, randomized, double-blind, placebo-controlled trial[J]. J Infect Dis, 2022, 225(6): 1091-1099.
[38] WANG LL.Clinical study of compound Biejia Ruangan tablet combined with adefovir dipivoxil in treating chronic hepatitis B liver fibrosis[J]. Asia-Pacific Traditional Medicine(亚太传统医药), 2017, 13(9): 136-137.
[39] DESJARDINS EM, WU J, LAVOIE DCT, et al.Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice[J]. Cell Rep Med, 2023, 4(9): 101193.
[40] MOON JS, HONG JH, JUNG YJ, et al.SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease[J]. Trends in Endocrinology and Metabolism, 2022, 33(6): 424-442.
[41] YANG T, YU B, LIU LP.Analysis of outpatient prescriptions of antihypertensive drugs in a 3A hospital during 2010-2012[J]. Anhui Medical and Pharmaceutical Journal(安徽医药), 2013, 17(7): 1250-1252.
[42] GAO ZQ, HU YP.Characteristics and rationality of the combination of antihypertensive drugs in clinic[J]. Clinical Research and Practice(临床医学研究与实践), 2018, 3(19): 102-103.
[43] WU XM, HE Q, YOU SJ, et al.General introduction of research progress on the mechanism of anti-hepatic fibrosis action of traditional Chinese medicine compound[J]. Beijing Journal of Traditional Chinese Medicine(北京中医药), 2021, 40(6): 675-680.
[44] LUO GA, LIANG QL, LIU JF, et al.Prospect on the composite drugs innovation system[J]. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology(世界科学技术-中医药现代化), 2009, 11(1): 3-10.
[45] WANG TY, WEI W, ZHONG H, et al.Progress on the treatment of metabolic dysfunction-associated fatty liver disease by farnesol X receptor agonist[J]. Chinese Journal of Liver Diseases (Electronic Version)(中国肝脏病杂志电子版), 2023, 15(1): 6-11.
[46] DAI S, WANG C.Effects of dapagliflozin combined with simeaglutide on glycolipid metabolism, liver function and liver fibrosis indexes in patients with type 2 diabetes mellitus complicated with metabolism-related fatty liver disease[J]. Diabetes New World(糖尿病新世界), 2023, 26(18): 25-29.
[47] QIAN SY, KANG CL.Consideration about compound medicine[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2015, 31(13): 1335-1337.
[48] ZHU WC, MO XC, SU HM, et al.Natural products against liver fibrosis by inhibiting the PI3K signaling pathway[J]. Chinese Pharmacological Bulletin(中国药理学通报), 2024, 40(4): 619-624.
[49] Chinese Society of Hepatology, Chinese Medical Association Chinese Society of Gastroenterology. Consensus on the diagnosis and treatment of hepatic fibrosis (2019)[J]. Journal of Digestive Diseases, 2020, 21(3): 127-138.
[50] LU LG, YOU H, XIE WF, et al.Consensus on the diagnosis and therapy of hepatic fibrosis[J]. Journal of Practical Hepatology(实用肝脏病杂志), 2019, 22(6): 793-803.
[51] FRIEDMAN SL, PINZANI M.Hepatic fibrosis 2022: unmet needs and a blueprint for the future[J]. Hepatology, 2021, 75(319): 473-488.
[52] DONG Q, BAO H, WANG J, et al.Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies[J]. Front Med(Lausanne), 2023, 10: 1120621.
[53] XIANG L, JIANG P, HU YH, et al.Progress and prospect on Polypill[J]. Journal of Pharmaceutical Practice and Service(药学实践杂志), 2012, 30(3): 161-164, 228.
[54] YAO W, WAN Z.Polypill Clinical research progress and application prospects[J]. Chinese Journal of Evidence-Based Medicine(中国循证心血管医学杂志), 2012, 4(6): 491-493.